Brar Sheetal, Ganesh Sri, Sriganesh Skanda Samak, Bhavsar Hemali
J Refract Surg. 2022 Jun;38(6):348-354. doi: 10.3928/1081597X-20220503-01. Epub 2022 Jun 1.
To report the long-term clinical experience following femtosecond intrastromal lenticule implantation (FILI) for the management of moderate to high hyperopia.
Eligible patients who underwent FILI for moderate to high hyperopia from July 2013 to October 2020 were included. A donor small incision lenticule extraction lenticule, matched for refractive error, was implanted into the recipient's corneal pocket created using a femtosecond laser at 160 µm depth. Visual and refractive outcomes and long-term complications were evaluated at the end of a mean follow-up of 68 ± 17.28 months (5.6 years).
Forty-two eyes of 25 patients (mean age: 27.29 ± 5.52 years) were analyzed. The mean spherical equivalent reduced significantly from +5.50 ± 1.96 to +0.66 ± 1.17 diopters (D) at last follow-up visit. Thirty eyes (71%) were within ±1.00 D of spherical equivalent correction. Cumulative uncorrected distance visual acuity of 20/40 or better was achieved in 34 eyes (81%). Efficacy and safety indices were 0.86 ± 0.19 and 1.17 ± 0.39, respectively. There was a significant increase in mean keratometry (Kmean) anterior, central corneal thickness, Q-value, and corneal higher order aberrations and a decrease in Kmean posterior 2 weeks postoperatively, without any significant change in these parameters thereafter ( > .05). Four eyes of 3 patients underwent enhancement and another 4 eyes underwent explantation of the lenticule followed by exchange (2 eyes) and hyperopic laser in situ keratomileusis (2 eyes). No eye lost more than one line of CDVA.
At 5 years of follow-up, FILI for moderate to high hyperopia showed good safety, efficacy, and reversibility. Modification of nomograms and surgical planning may be employed for further refinement of the outcomes. .
报告飞秒基质透镜植入术(FILI)治疗中高度远视的长期临床经验。
纳入2013年7月至2020年10月期间接受FILI治疗中高度远视的符合条件的患者。将根据屈光不正匹配的供体小切口透镜取出术透镜植入使用飞秒激光在160 µm深度创建的受体角膜袋中。在平均随访68±17.28个月(5.6年)结束时评估视觉和屈光结果以及长期并发症。
分析了25例患者的42只眼(平均年龄:27.29±5.52岁)。末次随访时平均等效球镜度从+5.50±1.96显著降低至+0.66±1.17屈光度(D)。30只眼(71%)的等效球镜矫正度在±1.00 D以内。34只眼(81%)实现了20/40或更好的累积未矫正远视力。疗效和安全指数分别为0.86±0.19和1.17±0.39。术后2周平均角膜曲率(Kmean)前、中央角膜厚度、Q值和角膜高阶像差显著增加,Kmean后降低,此后这些参数无显著变化(P>0.05)。3例患者的4只眼接受了增效治疗,另外4只眼接受了透镜取出术,随后进行了置换(2只眼)和远视准分子原位角膜磨镶术(2只眼)。没有一只眼的最佳矫正视力下降超过一行。
在5年的随访中,FILI治疗中高度远视显示出良好的安全性、有效性和可逆性。可采用调整列线图和手术规划进一步优化结果。